Company profile NVCR

NovoCure Ltd
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the... core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia. Show More
Quarter analysis & expected interest

There is not enough data for NovoCure -Medical Devices to provide analysis

Correlation between past revenue and NovoCure -Medical Devices search interest

There is not enough data for NovoCure -Medical Devices to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for NovoCure -Medical Devices to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Optune for glioblastoma to provide analysis

Correlation between past revenue and Optune for glioblastoma search interest

There is not enough data for Optune for glioblastoma to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Optune for glioblastoma to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Optune Lua for malignant pleural mesothelioma to provide analysis

Correlation between past revenue and Optune Lua for malignant pleural mesothelioma search interest

There is not enough data for Optune Lua for malignant pleural mesothelioma to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Optune Lua for malignant pleural mesothelioma to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TTFields devices to provide analysis

Correlation between past revenue and TTFields devices search interest

There is not enough data for TTFields devices to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TTFields devices to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for tumor treating fields devices to provide analysis

Correlation between past revenue and tumor treating fields devices search interest

There is not enough data for tumor treating fields devices to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for tumor treating fields devices to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 07:52:28.

After 39 days of this quarter the interest is at 60.0. Based on that we can calculate that during remaining 52 days it will total up to 140.0.
NovoCure Limited expected interest is significantly higher compared to same quarter last year (+677.8%) but similar to previous quarter.

YearQ1Q2Q3Q4
201999
51
-48.5% QoQ
50
-2.0% QoQ
91
82.0% QoQ
2020 96
-3.0% YoY 5.5% QoQ
150
194.1% YoY 56.2% QoQ
160
220.0% YoY 6.7% QoQ
45
-50.5% YoY -71.9% QoQ
2021 134
39.6% YoY 197.8% QoQ
125
-16.7% YoY -6.7% QoQ
133
-16.9% YoY 6.4% QoQ
52
15.6% YoY -60.9% QoQ
2022 162
20.9% YoY 211.5% QoQ
61
-51.2% YoY -62.3% QoQ
140
5.3% YoY 129.5% QoQ
83
59.6% YoY -40.7% QoQ
2023 18
-88.9% YoY -78.3% QoQ
77
26.2% YoY 327.8% QoQ
40
-71.4% YoY -48.1% QoQ
113
36.1% YoY 182.5% QoQ
2024 60
233.3% YoY -46.9% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and NovoCure Limited search interestLast update: February 09 2024 07:52:28.
Correlation coefficient between keyword and revenue is 0.19
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 07:52:29.

The average 5 years interest of NovoCure Limited was 7.43 per week.
The last year interest of NovoCure Limited compared to the last 5 years has changed by -24.9%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -0.36%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Novocure medical devices to provide analysis

Correlation between past revenue and Novocure medical devices search interest

There is not enough data for Novocure medical devices to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Novocure medical devices to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for NovoCure Oncology to provide analysis

Correlation between past revenue and NovoCure Oncology search interest

There is not enough data for NovoCure Oncology to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for NovoCure Oncology to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 07:52:34.

After 39 days of this quarter the interest is at 141.0. Based on that we can calculate that during remaining 52 days it will total up to 329.0.
NovoCure Optune expected interest is significantly higher compared to previous quarter (+545.1%) and same quarter last year (+422.2%).

YearQ1Q2Q3Q4
20190
172
inf% QoQ
189
9.9% QoQ
118
-37.6% QoQ
2020 113
inf% YoY -4.2% QoQ
49
-71.5% YoY -56.6% QoQ
86
-54.5% YoY 75.5% QoQ
115
-2.5% YoY 33.7% QoQ
2021 23
-79.6% YoY -80.0% QoQ
137
179.6% YoY 495.7% QoQ
256
197.7% YoY 86.9% QoQ
58
-49.6% YoY -77.3% QoQ
2022 46
100.0% YoY -20.7% QoQ
23
-83.2% YoY -50.0% QoQ
92
-64.1% YoY 300.0% QoQ
165
184.5% YoY 79.3% QoQ
2023 63
37.0% YoY -61.8% QoQ
188
717.4% YoY 198.4% QoQ
125
35.9% YoY -33.5% QoQ
51
-69.1% YoY -59.2% QoQ
2024 141
123.8% YoY 176.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and NovoCure Optune search interestLast update: February 09 2024 07:52:33.
Correlation coefficient between keyword and revenue is -0.04
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 07:52:35.

The average 5 years interest of NovoCure Optune was 8.47 per week.
The last year interest of NovoCure Optune compared to the last 5 years has changed by 28.93%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -4.04%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for NovoCure treatments to provide analysis

Correlation between past revenue and NovoCure treatments search interest

There is not enough data for NovoCure treatments to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for NovoCure treatments to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for NVCR
Earnings date: 2024-02-22 After close
Company name: NovoCure Ltd
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-04T18:57:59Z

Analyst Upgrades
Wells Fargo Maintains Equal-Weight on NovoCure, Raises Price Target to $17

2026-05-01T13:22:54Z

Analyst Upgrades
Evercore ISI Group Maintains Outperform on NovoCure, Raises Price Target to $20

2026-04-30T11:00:00Z

BusinessWire
Novocure Reports First Quarter 2026 Financial Results

2026-04-24T16:08:39-04:00

SEC
8-K/A Form - [Amend] Current report, items 5.02 and 9.01 - NovoCure Ltd (0001645113) (Filer)

2026-04-16T13:32:48Z

Analyst Upgrades
Wedbush Reiterates Neutral on NovoCure, Maintains $18 Price Target

2026-04-01T11:00:00Z

BusinessWire
Novocure to Report First Quarter 2026 Financial Results

2026-03-26T11:00:00Z

BusinessWire
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

2026-03-02T12:00:00Z

BusinessWire
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

2026-02-27T21:30:00Z

BusinessWire
Novocure to Participate in 2026 Leerink Global Healthcare Conference

2026-02-26T18:48:40Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $49

2026-02-26T12:00:00Z

BusinessWire
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

2026-02-25T09:00:00-05:00

PR Newswire
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026

2026-02-24T12:00:00Z

BusinessWire
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

2026-02-17T11:25:00-05:00

PR Newswire
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else

2026-02-17T11:17:00-05:00

PR Newswire
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else